We employ cookies for advertising, analytics, and to improve your experience using our website. By continuing to use our site, you agree to our use of cookies. For more information, please see our Privacy Policy.
According to the Center for Disease Control (CDC) it is estimated that 1.8 million Americans aged 40 years and older are affected by age-related macular degeneration (AMD), and an additional 7.3 million with large drusen are at substantial risk of developing AMD. The number of people in the US with AMD is estimated to reach 3 million in 2020. AMD is the leading cause of permanent impairment of reading and fine or close-up vision among people 65 years and older.
In May 2013, the National Eye Institute completed the Age-Related Eye Disease Study 2 (AREDS 2) which tested several changes to the original AREDS 1 study. The study found that the addition of lutein and zeaxanthin (while removing beta-carotene) had a significant reduced risk of developing advanced AMD.
Eye Care and Cure is offering to your office (for resale to your patients) the LuxVite™ AREDS 2 product.